Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
30
08
2023
accepted:
13
09
2024
revised:
05
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
aheadofprint
Résumé
Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P < 0.001) and +1.0 years in the CUMC cohort (P < 0.001). While additional studies are needed, this study supports the potential roles of heparin-like drugs and HSPGs in the protection from and prevention of AD dementia.
Identifiants
pubmed: 39379683
doi: 10.1038/s41380-024-02757-5
pii: 10.1038/s41380-024-02757-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
ID : R01AG054671
Informations de copyright
© 2024. The Author(s).
Références
Saroja SR, Gorbachev K, Julia T, Goate AM, Pereira AC. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. Proc Natl Acad Sci USA 2022;119:e2108870119.
doi: 10.1073/pnas.2108870119
pubmed: 35969759
pmcid: 9407658
Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 2013;110:E3138–3147.
doi: 10.1073/pnas.1301440110
pubmed: 23898162
pmcid: 3746848
Rauch JN, Chen JJ, Sorum AW, Miller GM, Sharf T, See SK, et al. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci Rep. 2018;8:6382.
doi: 10.1038/s41598-018-24904-z
pubmed: 29686391
pmcid: 5913225
Zhao J, Zhu Y, Song X, Xiao Y, Su G, Liu X, et al. 3-O-Sulfation of Heparan Sulfate Enhances Tau Interaction and Cellular Uptake. Angew Chem Int Ed Engl. 2020;59:1818–27.
doi: 10.1002/anie.201913029
pubmed: 31692167
Weisova P, Cehlar O, Skrabana R, Zilkova M, Filipcik P, Kovacech B, et al. Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathol Commun. 2019;7:129.
doi: 10.1186/s40478-019-0770-y
pubmed: 31391090
pmcid: 6685285
Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease. Nat Med. 2023;29:1979–88.
doi: 10.1038/s41591-023-02476-4
pubmed: 37550416
pmcid: 10427428
Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci. 2022;25:213–25.
doi: 10.1038/s41593-021-00999-y
pubmed: 35115731
pmcid: 8825285
Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression. Neuron. 2020;105:975–91.e977.
doi: 10.1016/j.neuron.2019.12.015
pubmed: 31926610
pmcid: 7318843
Witoelar A, Rongve A, Almdahl IS, Ulstein ID, Engvig A, White LR, et al. Meta-analysis of Alzheimer’s disease on 9751 samples from Norway and IGAP study identifies four risk loci. Sci Rep. 2018;8:18088.
doi: 10.1038/s41598-018-36429-6
pubmed: 30591712
pmcid: 6308232
Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P T. 2010;35:95–105.
pubmed: 20221326
pmcid: 2827912
Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25:5–16.
pubmed: 10549711
Bohdan N, Espin S, Aguila S, Teruel-Montoya R, Vicente V, Corral J, et al. Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site. PLoS One. 2016;11:e0157834.
doi: 10.1371/journal.pone.0157834
pubmed: 27322195
pmcid: 4913942
Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest. 1984;74:341–50.
doi: 10.1172/JCI111429
pubmed: 6746897
pmcid: 370484
Warnock LB, Huang D. Heparin. Treasure Island (FL): StatPearls; 2021.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Schuemie M, Suchard M, Ryan P, Reps J, Sena A, Inberg G. FeatureExtraction: Generating Features for a Cohort. R package version 3.7.1, 2024. https://github.com/OHDSI/FeatureExtraction .
Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3.
doi: 10.1038/s41591-019-0611-3
pubmed: 31686034
pmcid: 6898984
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74.
doi: 10.1016/S1474-4422(05)70284-2
pubmed: 16361024
Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer’s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 2005;53:1101–7.
doi: 10.1111/j.1532-5415.2005.53360.x
pubmed: 16108925
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–22.
doi: 10.1056/NEJMoa022066
pubmed: 12660385
Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914–22.
doi: 10.1212/WNL.0b013e31820f2e38
pubmed: 21383328
Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 2006;66:1399–404.
doi: 10.1212/01.wnl.0000210447.19748.0b
pubmed: 16682673
Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev. 2002;8:1–30.
doi: 10.1111/j.1527-3458.2002.tb00213.x
pubmed: 12070524
pmcid: 6741656